Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric

REPRONEX

MENOTROPINS (FSH;LH)

Standard Dose
75 IU/VIAL;75 IU/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview REPRONEX is listed in Drugs@FDA under application 021047 (BLA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient MENOTROPINS (FSH;LH) Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL;75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-03-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview REPRONEX is listed in Drugs@FDA under application 021047 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MENOTROPINS (FSH;LH) Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 75 IU/VIAL;75 IU/VIAL Sponsor FERRING Submission history Latest submission status date: 2015-03-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
REPRONEX (MENOTROPINS (FSH;LH)) | Drug Monograph | MedicHelpline